迪奥斯通过增加Akkermansia muciniphila的丰富性,改善肠道屏障功能,并调节NF-κB和Nrf2通路来缓解小鼠的性结肠炎
Maha Badr Salem1, Naglaa Mohamed El-Lakkany1, Sayed Hassan Seif El-Din1
1Department of Pharmacology, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, Giza, 12411, Egypt.
Heliyon
|March 19, 2024
概括
迪奥斯 (DIO) 通过减少炎症和氧化应激,有效治疗性结肠炎. 它还增强了肠道屏障功能,并在小鼠模型中增加了有益的Akkermansia muciniphila丰度.
科学领域:
- 胃肠病学和肝病学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种普遍存在的炎症性肠病,具有复杂的潜在原因,包括氧化应激,炎症和肠道微生物群失调.
- 目前的UC治疗往往侧重于免疫抑制,需要研究针对根源原因的治疗方法.
- 迪奥斯 (DIO) 是一种天然的黄类化合物,具有已知的抗氧化和抗炎性质,这表明UC的治疗潜力.
研究的目的:
- 评估迪奥斯 (DIO) 在硫酸 (DSS) 诱导的大肠炎的小鼠模型中的疗效.
- 调查DIO的作用机制,重点关注其对Akkermansia muciniphila丰度,炎症标志物和肠道屏障完整性的影响.
主要方法:
- 在C57BL/6小鼠中使用4%的DSS诱导大肠炎.
- 小鼠每天接受口服DIO (100和200毫克/公斤) 或硫沙拉,持续7天.
- 每天评估疾病活动指数 (DAI);分析了便中的Akkermansia muciniphila丰度,结肠MUC1 / MUC2表达,氧化应激,炎症标志物 (NF-κB, Nrf2),PIK3R3,ZO-1,ocludin和claudin-1.
主要成果:
- DIO的使用量依赖于降低了DAI,增加了Akkermansia muciniphila的丰度,并调节了MUC1/MUC2的表达.
- 通过调节NF-κB和Nrf2通路,DIO显著降低了结肠氧化应激和炎症.
- 通过抑制PIK3R3,诱导ZO-1和改善奥克卢丁/克劳丁-1表达,DIO恢复了肠道屏障的完整性.
结论:
- 迪奥斯 (DIO) 在治疗DSS诱导的大肠炎,维护肠道屏障完整性和增加Akkermansia muciniphila丰富性方面表现出有效性.
- DIO的治疗作用与其抗氧化,抗炎和肠道屏障保护性有关.
- 需要进一步的研究来探索DIO对肠道微生物群的整体组成的影响以及UC治疗中的Akkermansia muciniphila的特定机制.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
139
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
139
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
429
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
429
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


